Clinical trials: Glioma
Malignant Glioma, Glioblastoma Multiforme
Dendritic Cell (DC) Vaccine for Malignant Glioma and Glioblastoma
The purpose of this research study is to evaluate an investigational vaccine using patent-derived dendritic cells (DC) to treat malignant glioma or glioblastoma.
- Conditions
- Malignant Glioma, Glioblastoma Multiforme, Anaplastic Astrocytoma, High Grade Glioma
- Trial name
- NCT01808820
- Testing
- Dendritic Cell Vaccine, Tumor Lysate, Imiquimod
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Macarena De La Fuente, MD
Glioma, Brain Metastases
Efficacy and Safety Evaluation of Percutaneous Ommaya Capsule Injection of Autologous Bi-dimensional Specific T Cells in the Treatment of Glioma and in Combination With Pemetrexed in the Treatment of Brain/Meningeal Metastases
Cerebral metastases are common intracranial tumor, its incidence increased year by year, in recent years, although the whole brain radiation therapy, surgical resection, stereotactic radiosurgery treatment, targeted drugs, and…
- Trial name
- NCT05459441
- Testing
- Autologous progenitor expansion -T, pemetrexed
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai Pudong Hospital
Low Grade Glioma
Ovarian Aging in Low Grade Glioma (LGG) Treated With Temozolomide
The purpose of this study is to look at how a chemotherapy treatment (Temozolomide, also called Temodar) affects the process of ovarian aging which is measured by a decline in ovarian follicle count, in patients with Low Grade…
- Trial name
- OVA-LGG (NCT01452854)
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of California, San Francisco
Glioblastoma
Avelumab With Hypofractionated Radiation Therapy in Adults With Isocitrate Dehydrogenase (IDH) Mutant Glioblastoma
The purpose of this study is to test how safe and effective treatment with the combination of Avelumab and radiation is for IDH mutant gliomas that have transformed to glioblastoma after chemotherapy.
- Trial name
- NCT02968940
- Testing
- Avelumab, Hypofractionated radiation therapy (HFRT)
- Where
- 4 sites in United States
- Volunteers
- 6 people
- Sponsor
- NYU Langone Health
Medulloblastoma, Astrocytoma, Grade III
Phase I Study of Mebendazole Therapy for Recurrent/Progressive Pediatric Brain Tumors
This is a safety (Phase 1) trial using mebendazole for recurrent pediatric brain cancers that include medulloblastoma and high grade glioma, that are no longing responding to standard therapies.
- Conditions
- Medulloblastoma, Astrocytoma, Grade III, Glioblastoma, Anaplastic Astrocytoma
- Trial name
- NCT02644291
- Testing
- Mebendazole
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Glioblastoma Multiforme, Glioblastoma
TTFields and Pulsed Bevacizumab for Recurrent Glioblastoma
Glioblastoma multiforme (GBM) is the most common and deadliest primary malignant neoplasm of the central nervous system in adults.
- Conditions
- Glioblastoma Multiforme, Glioblastoma, Malignant Glioma, GBM
- Trial name
- NCT02663271
- Testing
- Bevacizumab, Optune, Brain MRI
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- University of Florida
Glioblastoma Multiforme, Brain Neoplasms
A Phase 1 / 2 Dose Escalation Study of Locally-Administered OncoGel™ in Subjects With Recurrent Glioma
OncoGel™ is a new, experimental drug delivery system that allows the slow continuous release of paclitaxel (an approved intravenous anticancer drug), from a gel (ReGel™) over a long period of time.
- Trial name
- NCT00479765
- Testing
- OncoGel (ReGel/Paclitaxel)
- Where
- 5 sites in United States
- Volunteers
- 4 people
- Sponsor
- Boston Scientific Corporation
Glioma, Malignant
Establishing Radiolabelled PSMA as a Target for Glioma Treatment
A study is being performed to observe whether a novel type of brain imaging using a technique called PET-MRI may provide useful information in the 'mapping' of adult primary brain tumours.
- Trial name
- NCT05263466
- Testing
- PET-MRI, Brain tumour biopsy
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- King's College Hospital NHS Trust
Central Nervous System Lymphoma, Malignant Glioma
Ferumoxytol in Improving MR Imaging in Patients With High-Grade Brain Tumors or Cerebral Metastases
This clinical trial studies magnetic resonance imaging (MRI) using a contrast imaging agent ferumoxytol (ferumoxytol non-stoichiometric magnetite) in improving viewing tumors in patients with high-grade brain tumors or cancer…
- Conditions
- Central Nervous System Lymphoma, Malignant Glioma, Metastatic Malignant Neoplasm in the Brain
- Trial name
- NCT00103038
- Testing
- 3 Tesla Magnetic Resonance Imaging, Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging
- Where
- United States
- Volunteers
- 155 people
- Sponsor
- OHSU Knight Cancer Institute
Malignant Glioma, Glioblastoma
Stage 1: Marizomib + Bevacizumab in WHO Gr IV GBM; Stage 2: Marizomib Alone; Stage 3: Combination of Marizomib and Bevacizumab
This is a Phase 1/2 clinical trial to evaluate a new combination of drugs, marizomib (MRZ) and bevacizumab (BEV; Avastin®), for the treatment of WHO Grade IV malignant glioma.
- Trial name
- NCT02330562
- Testing
- MRZ, BEV
- Where
- 5 sites in United States, Canada
- Volunteers
- 121 people
- Sponsor
- Celgene
Glioblastoma WHO Grade IV, Diffuse Midline Glioma Histone 3 K27M WHO Grade IV
International Cooperative Phase III Trial of the HIT-HGG Study Group (HIT-HGG-2013)
The HIT-HGG-2013 trial offers an innovative high-quality diagnostics and science program for children and adolescents >3 years, suffering from one of the following types of high grade gliomas: 1.
- Conditions
- Glioblastoma WHO Grade IV, Diffuse Midline Glioma Histone 3 K27M WHO Grade IV, Anaplastic Astrocytoma WHO Grade III, Diffuse Intrinsic Pontine Glioma
- Trial name
- HIT-HGG-2013 (NCT03243461)
- Testing
- Temozolomide + Valproic Acid
- Where
- 51 sites in Germany
- Volunteers
- 167 people
- Sponsor
- University of Göttingen
Brain Tumor, Glioblastoma
Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas
The goal of Phase 1 of this clinical research study is to find the highest tolerable dose and best schedule of the combination of everolimus and sorafenib that can be given to patients with malignant glioma.
- Conditions
- Brain Tumor, Glioblastoma, Anaplastic Glioma
- Trial name
- NCT01434602
- Testing
- everolimus, sorafenib
- Where
- United States
- Volunteers
- 86 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Glioma
Study of the Anti-tumoral Immune Response
This study evaluates the frequency of the spontaneous T cells specific CD4 answers of tumoral antigens breast cancer and glioma.
- Trial name
- ERISA (NCT02854644)
- Testing
- additional blood sample
- Where
- France
- Volunteers
- 167 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Glioma Glioblastoma Multiforme
Functional and Ultrasound Guided Resection of Glioblastoma
Functional and ultrasound-guided resection of glioblastoma: assessing the use of additional imaging during surgery to improve outcomes for patients with glioblastoma brain tumours
- Trial name
- FUTURE-GB (NCT05399524)
- Testing
- Standard of Care, Additional pre- and intra-operative imaging
- Where
- 24 sites in United Kingdom
- Volunteers
- 357 people
- Sponsor
- University of Oxford
Refractory Low-grade Gliomas, Recurrent Low-grade Gliomas
Study of Vinblastine in Combination With Nilotinib in Children, Adolescents, and Young Adults
Multicenter, open label, prospective study including successively a phase I trial and then a phase II trial Phase I : Open label, non-randomized, sequential dose escalation of both drugs, vinblastine and nilotinib.
- Trial name
- VINILO (NCT01887522)
- Testing
- Vinblastine + Nilotinib, Vinblastine
- Where
- 8 sites in Austria, Denmark and 6 more
- Volunteers
- 144 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Brain Tumor, Glioma
Novel Exoscope System for 5-ALA Fluorescence-Guided Surgery for Gliomas
5-ALA and the Orbeye surgical microscope are U.S. Food and Drug Administration (FDA) approved products. For this study, the Orbeye microscope imaging system is being used with special filters to visualize 5-ALA fluorescence.
- Trial name
- NCT04055688
- Testing
- Orbeye surgical videomicroscope, 5-Aminolevulinic Acid
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Refractory Low-grade Gliomas, Recurrent Low-grade Gliomas
Study Of Vinblastine in Combination With Nilotinib in Children, Adolescents and Young Adults
Multicenter, open label, prospective study including successively a phase I trial and then a phase II trial Phase I : Open label, non-randomized, sequential dose escalation of both drugs, vinblastine and nilotinib.
- Trial name
- VINILO (NCT01884922)
- Testing
- Nilotinib, Vinblastine
- Where
- 8 sites in Austria, Denmark and 6 more
- Volunteers
- 35 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Glioma
Expanded Access Use of ONC201 in a Patient With Diffuse Intrinsic Pontine Gliomas
This is an intermediate-size expanded access protocol to provide ONC201 to patients with diffuse intrinsic pontine gliomas who cannot access ONC201 through clinical trials.
- Trial name
- NCT05392374
- Testing
- ONC201
- Where
- 10 sites in United States
- Sponsor
- Jazz Pharmaceuticals
Glioblastoma Multiforme, Glioblastoma
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
The primary purpose of the study is to determine the efficacy of an investigational therapy called DCVax(R)-L in patients with newly diagnosed GBM for whom surgery is indicated.
- Conditions
- Glioblastoma Multiforme, Glioblastoma, GBM, Grade IV Astrocytoma
- Trial name
- GBM (NCT00045968)
- Testing
- Dendritic cell immunotherapy
- Where
- 86 sites in United States, Canada and 2 more
- Volunteers
- 348 people
- Sponsor
- Northwest Biotherapeutics
High Grade Glioma
Glioma and Exercising
To investigate the influence of two physical activity and exercising (PAE) interventions, namely resistance training and endurance training in relation to quality of life, depression, fatigue, sleep, anxiety, stress and coping…
- Trial name
- NCT03775369
- Testing
- endurance training, social support and counseling, resistance training
- Where
- 2 sites in Switzerland
- Volunteers
- 39 people
- Sponsor
- University Hospital, Basel, Switzerland